Etanercept-induced pleuropericardial lupus-like syndrome: Fig. 1—

Porfyridis, Ilias; Kalomenidis, I.; Psallidas, Ioannis; Stratakos, Grigorios; Roussos, Charalambos; Vassilakopoulos, T.; Stathopoulos, Georgios T.

doi:10.1183/09031936.00182308

Cited by 12 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over 1500 people per million population develop an exudative pleural effusion a year; pleural infection and malignant pleural effusion (MPE) being the leading causes. Active plasma extravasation from juxtapleural hyperpermeable blood vessels is a cardinal mechanism of effusion development 29,[37][38][39][40][41][42][43] and has been shown in animal models of various pleural effusions [44][45][46][47][48][49][50] .…”

Section: Medical Regulation Of Pleural Fluid Formationmentioning

confidence: 99%

Translational Research in Pleural Infection and Beyond

Lee

Idell

Stathopoulos

2016

Chest

View full text Add to dashboard Cite

The incidence of pleural infection has been rising in recent years. Intrapleural therapy with tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) has significantly reduced the need for surgery, and its impact on clinical care is rising worldwide. Efforts are underway to optimize the delivery regimen and establish the short and longer term effects of this therapy. The complex interactions of bacterial infection within the pleura with inflammatory responses and clinical interventions (antibiotics and tPA/DNase or other fibrinolysins) require further studies to improve future treatment options. Intrapleural instillation of tPA potently induces pleural fluid formation, principally via a monocyte chemotactic protein (MCP)-1 dependent mechanism. Activation of transcriptional programs in pleural resident cells and infiltrating cells during pleural infection and malignancy results in the local secretion of a cocktail of proinflammatory signaling molecules (including MCP-1) within the pleural confines that contributes to effusion formation. Understanding the biology of these molecules and their interaction may provide novel targets for pleural fluid control.

show abstract

Section: Medical Regulation Of Pleural Fluid Formationmentioning

confidence: 99%

Translational Research in Pleural Infection and Beyond

Lee

Idell

Stathopoulos

2016

Chest

View full text Add to dashboard Cite

show abstract

“…There does not appear to be any association with pretreatment antibody profiles. Several case reports of serositis associated with anti-TNF-α agents have already been described 27 28…”

Section: Discussionmentioning

confidence: 99%

Adalimumab-induced lupus serositis

2015

View full text Add to dashboard Cite

SUMMARYA 61-year-old man presented with a 1-month history of breathlessness, chest pain and lethargy. He had been taking adalimumab for ankylosing spondylitis for 2 years. Pleural and pericardial effusions were both found. A video-assisted thorascopic (VATS) pleural and lung biopsy were performed. The pleural pathology showed eosinophils, acute inflammatory cells and lymphoid aggregates. The patient was positive for antinuclear, antidouble-stranded and antihistone antibodies consistent with drug-induced lupus due to adalimumab. His serositis resolved on withdrawal of the drug. Drug-induced lupus can occur as a consequence of anti-TNF-α agents from induction of autoimmunity in a predisposed host. BACKGROUND

show abstract

“…Профиль аутоантител при синдроме ЛВ скудный. Редко выявляются антитела к Sm-антигену и двуспиральной ДНК (дсДНК; последние регистрировались у больных, получавших сульфасалазин и иФНОα) [31]. Напротив, антитела к односпиральной ДНК встречаются часто.…”

Section: клинико-лабораторная характеристикаunclassified

Drug-induced lupus

Клюквина¹,

Гунчикова

Aa³

2018

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Drug-induced lupus (DIL) is an autoimmune phenomenon that has similar clinical and laboratory manifestations with idiopathic systemic lupus erythematosus (SLE). About 100 drugs are now known to be associated with the development of DIL. Its diagnosis is verified in the presence of a chronological relationship between the long-term administration of drugs and the mandatory presence of one clinical and one laboratory diagnostic criteria for SLE.The paper deals with the etiology, pathogenesis, and differential diagnosis of DIL. It presents a spectrum of drugs that can cause DIL and considers the features of its different forms.Based on the recent data available in the literature, the authors analyze the occurrence of autoimmune responses due to the useof biologic agents (BAs), primarily tumor necrosis factor-αinhibitors. Therapeutic approaches for DIL are discussed. Recommendations are given for screening the patients in the use of BAs. Clinical examples are provided.

show abstract

Etanercept-induced pleuropericardial lupus-like syndrome: Fig. 1—

Cited by 12 publications

References 11 publications

Translational Research in Pleural Infection and Beyond

Translational Research in Pleural Infection and Beyond

Adalimumab-induced lupus serositis

Drug-induced lupus

Contact Info

Product

Resources

About